VERONA PHARMA PLC - ADR (VRNA) Stock Overview
USA - NASDAQ:VRNA - US9250501064 - ADR
VRNA Key Statistics, Chart & Performance
The current stock price of VRNA is 106.255 USD. In the past month the price increased by 0.54%. In the past year, price increased by 253.52%.
VRNA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.75 | 714.60B | ||
| JNJ | JOHNSON & JOHNSON | 17.43 | 419.77B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 15.47 | 270.23B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 17.5 | 240.91B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.96 | 239.25B | ||
| MRK | MERCK & CO. INC. | 10.45 | 201.02B | ||
| PFE | PFIZER INC | 7.1 | 136.79B | ||
| SNY | SANOFI-ADR | 10.59 | 114.90B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.69 | 91.67B | ||
| GSK | GSK PLC-SPON ADR | 9.05 | 82.45B | ||
| ZTS | ZOETIS INC | 23.27 | 64.13B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 51.81 | 47.45B |
Related stock screener links
About VRNA
Company Profile
Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. The firm is focused on developing and commercializing therapies for the treatment of chronic respiratory diseases with unmet medical needs. Ohtuvayre (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of chronic obstructive pulmonary disease (COPD) that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. The firm has evaluated nebulized Ohtuvayre in its Phase III clinical program ENHANCE (Ensifentrine as an Inhaled Nebulized COPD therapy) for COPD maintenance treatment. The company has developed formulations of ensifentrine for the three inhalation devices: nebulizer, dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). Ensifentrine has potential in other respiratory diseases such as non-cystic fibrosis bronchiectasis. The firm's subsidiaries include Verona Pharma, Inc. and Verona Pharma Ireland Limited.
Company Info
VERONA PHARMA PLC - ADR
Riverside, 3 More London Place
London SE1 2RE GB
CEO: David Zaccardelli
Employees: 209
Phone: 442032834200
VERONA PHARMA PLC - ADR / VRNA FAQ
What is the stock price of VERONA PHARMA PLC - ADR today?
The current stock price of VRNA is 106.255 USD. The price increased by 0.22% in the last trading session.
What is the ticker symbol for VERONA PHARMA PLC - ADR stock?
The exchange symbol of VERONA PHARMA PLC - ADR is VRNA and it is listed on the Nasdaq exchange.
On which exchange is VRNA stock listed?
VRNA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for VERONA PHARMA PLC - ADR stock?
18 analysts have analysed VRNA and the average price target is 108.43 USD. This implies a price increase of 2.04% is expected in the next year compared to the current price of 106.255. Check the VERONA PHARMA PLC - ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is VERONA PHARMA PLC - ADR worth?
VERONA PHARMA PLC - ADR (VRNA) has a market capitalization of 9.19B USD. This makes VRNA a Mid Cap stock.
How many employees does VERONA PHARMA PLC - ADR have?
VERONA PHARMA PLC - ADR (VRNA) currently has 209 employees.
What are the support and resistance levels for VERONA PHARMA PLC - ADR (VRNA) stock?
VERONA PHARMA PLC - ADR (VRNA) has a support level at 106.01 and a resistance level at 106.11. Check the full technical report for a detailed analysis of VRNA support and resistance levels.
Is VERONA PHARMA PLC - ADR (VRNA) expected to grow?
The Revenue of VERONA PHARMA PLC - ADR (VRNA) is expected to grow by 1008.75% in the next year. Check the estimates tab for more information on the VRNA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy VERONA PHARMA PLC - ADR (VRNA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of VRNA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of VRNA, evaluating the profitability, health, valuation and growth aspects
- VERONA PHARMA PLC - ADR (VRNA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- VERONA PHARMA PLC - ADR (VRNA) Sales and EPS estimates to see what analysts future expectations are.
- VERONA PHARMA PLC - ADR (VRNA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- VERONA PHARMA PLC - ADR (VRNA) Insider and Institutional Ownership to learn about the owners and their transactions.
- VERONA PHARMA PLC - ADR (VRNA) Stock Chart to make your own analysis
- VERONA PHARMA PLC - ADR (VRNA) Latest news and press-releases to stay up to date.
Does VERONA PHARMA PLC - ADR (VRNA) stock pay dividends?
VRNA does not pay a dividend.
When does VERONA PHARMA PLC - ADR (VRNA) report earnings?
VERONA PHARMA PLC - ADR (VRNA) will report earnings on 2025-11-03.
What is the Price/Earnings (PE) ratio of VERONA PHARMA PLC - ADR (VRNA)?
VERONA PHARMA PLC - ADR (VRNA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.99).
What is the Short Interest ratio of VERONA PHARMA PLC - ADR (VRNA) stock?
The outstanding short interest for VERONA PHARMA PLC - ADR (VRNA) is 2.74% of its float. Check the ownership tab for more information on the VRNA short interest.
VRNA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to VRNA. When comparing the yearly performance of all stocks, VRNA is one of the better performing stocks in the market, outperforming 97.22% of all stocks.
VRNA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to VRNA. The financial health of VRNA is average, but there are quite some concerns on its profitability.
VRNA Financial Highlights
Over the last trailing twelve months VRNA reported a non-GAAP Earnings per Share(EPS) of -0.99. The EPS increased by 36.54% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.17% | ||
| ROE | -72.35% | ||
| Debt/Equity | 1.07 |
VRNA Forecast & Estimates
18 analysts have analysed VRNA and the average price target is 108.43 USD. This implies a price increase of 2.04% is expected in the next year compared to the current price of 106.255.
For the next year, analysts expect an EPS growth of 123.49% and a revenue growth 1008.75% for VRNA